

UPMC Hillman Cancer Center, Partner with University of Pittsburgh Cancer Institute, and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences presents:

2024 UPMC Hillman Cancer Center: Advancements in Head and Neck Cancer Conference

Date: Saturday, October 26, 2024

Time: 9:00 am to 4:30 pm

Location: The Assembly (Pittsburgh) and Microsoft TEAMS

Course Directors

Matthew Spector, MD

Chief, Division of Head and Neck Surgical Oncology and Microvascular Reconstruction Director, Head and Neck Surgical Oncology and Microvascular Reconstruction Fellowship Professor of Otolaryngology University of Pittsburgh

Christopher Wilke, MD

Clinical Associate Professor, Department of Radiation Oncology, UPMC Hillman Cancer Center

Dan P Zandberg, MD

Associate Professor of Medicine, Director, Head and Neck and Thyroid Cancer Disease Sections Director of Clinical Affairs, Division of Hematology/Oncology UPMC Hillman Cancer Center

Program Goal

This program is designed to facilitate collaboration among health care workers who treat patients with head and neck cancer. Participants will discuss advances in head and neck cancer, including treatment options and patient education.

Target Audience

Physicians, advanced practice providers, nurses, and other health care professionals who work with individuals with head and neck cancer.

Course Objectives

Upon completion of this program, attendees will be able to:

- Discuss the standard of care evaluation and treatment of squamous cell carcinoma of the oral cavity, oropharynx (HPV negative), larynx, hypopharynx, nasopharynx, and paranasal sinus.
- Discuss the standard of care evaluation and treatment of HPV positive oropharyngeal squamous cell carcinoma.
- Discuss the standard of care evaluation and treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
- Describe new developments in clinical, translational, and basic immunology in head and neck cancer.

Tuition and Registration

Tuition for physicians is \$75.00. Tuition for all other medical professionals is \$35.00. There is no fee for students. For more information, contact Lynne O'Connor at connorlj@upmc.edu. Course brochure and registration are available at <http://cce.upmc.com>. **Registration deadline is Friday, October 18, 2024.** Cancellations received before Friday, October 18, 2024, will be refunded in full. After Friday, October 18, 2024, no refunds will be made.

The Americans with Disabilities Act Information

Participation by all individuals is encouraged. Advanced notification of any special needs will help us provide better service. Please notify Lynne O'Connor of your needs at least two weeks in advance of the program by emailing connorlj@upmc.edu. The University of Pittsburgh is an affirmative action, equal opportunity institution.

Accreditation and Credit Designation

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Disclaimer

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC Affiliates, and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

We gratefully acknowledge support from the following exhibitors for this activity:

Bayer Pharmaceuticals, NeoGenomics Laboratories, and Merck

Faculty

Diana M. Bell, MD

*Professor of Pathology, Head and Neck
Division of Anatomic Pathology
University of Pittsburgh Medical Center*

Garret W. Choby, MD

*Associate Professor
Departments of Otolaryngology
and Neurological Surgery*

Kevin J. Contrera, MD, MPH

*Head and Neck Surgical Oncology
and Microvascular Reconstruction
Assistant Professor,
Department of Otolaryngology
University of Pittsburgh Medical Center*

Zahra Kelly, DO

*Clinical Instructor of Medicine
UPMC Hillman Cancer Center*

Seungwon W. Kim, MD

*Associate Professor, Department of
Otolaryngology-Head and Neck
Surgery*

Nancy Lee, MD, FASTRO

*Vice Chairman of Radiation Oncology
Experimental Therapeutics
Chief, Head and Neck Radiation
Oncology
Director, Proton Therapy
Member, Memorial Sloan-Kettering
Cancer Center
Medical Director and President of New
York Proton Consortium-NJ*

Yvonne M. Mowery, MD, PhD

*Associate Professor of Radiation
Oncology
UPMC Hillman Cancer
Center/University of Pittsburgh*

**Marci Lee Nilsen, PhD, RN, CHPN,
FAAN**

*Assistant Professor
Department of Acute and Tertiary
Care, School of Nursing
Department of Otolaryngology, School
of Medicine
Fellow, Betty Irene Moore Fellowship
for Nurse Leaders and Innovators
Co-Director, UPMC Head and Neck
Cancer Survivorship*

Shaum Sridharan, MD

*Associate Professor, Department of
Otolaryngology-Head and Neck
Surgery
Associate Director, Advanced Head
and Neck Surgical Oncology
Fellowship*

Matthew E. Spector, MD, FACS

*Chief, Division of Head and Neck
Surgical Oncology and Microvascular
Reconstruction
Director, Head and Neck Surgical
Oncology and Microvascular
Reconstruction Fellowship
Professor of Otolaryngology
University of Pittsburgh*

Christopher Wilke, MD, PHD

*Clinical Assistant Professor
Department of Radiation Oncology
UPMC Hillman Cancer Center*

Dan Zandberg, MD

*Associate Professor of Medicine,
Director, Head and Neck and Thyroid
Cancer Disease sections
Director of Clinical Affairs,
Division of Hematology/Oncology
UPMC Hillman Cancer Center*

José Zevallos, MD, MPH, FACS

*The Eugene N. Myers, M.D. Professor
and Chair
University of Pittsburgh Physicians
Department of Otolaryngology*

Faculty Disclosures

All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All the relevant financial relationships for the individuals listed below have been mitigated:

Yvonne M. Mowery, MD, PhD (Consultant: Up To Date, Catalys Pacific LLC. Grant/Research Support: Bayer, Merck)

Matthew Spector, MD (Consultant: Hologic)

Christopher Wilke, MD (Consultant: Kallisto)

Dan Zandberg, MD (Consultant: Inhibrx, Merck, MacroGenetics, BICARA, Seagen. Grant/Research Support: Merck, BMS, ISA therapeutics, BICARA, Novocenta, Aldai Nortye, Aveo)

Jose Zevallos, MD (Consultant; Johnson and Johnson, Merck. Stockholder (privately held): Droplet Biosciences, Vine Medical, Echogenesis)

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Agenda

8:15 am - 9:00 am	Registration and Breakfast (Live Attendees) TEAMS login (Virtual Attendees)	
9:00 am - 9:05 am	Welcome and Opening Remarks	Dan Zandberg, MD
	<i>Larynx, Hypopharynx, and HPV Negative Oropharyngeal SCC</i> <i>Moderator: Shaum Sridharan, MD</i>	
9:05 am - 9:20 am	Surgical Techniques for Laryngeal Cancer	Shaum Sridharan, MD
9:20 am - 9:35 am	Organ Preservation in Laryngeal and Hypopharyngeal Cancer	Christopher Wilke, MD
9:35 am - 9:50 am	Escalation Efforts to Improve Outcomes in HPV-Negative HNSCC	Zahara Kelly, MD
9:50 am - 10:05 am	Panel: Larynx and Hypopharynx Cases	
10:05 am - 10:20 am	Break	
	<i>HPV Positive Oropharyngeal SCC</i> <i>Moderator: Jose Zevallos</i>	
10:20 am - 10:50 am	Keynote Speaker: De-escalation Therapy in HPV Positive OPC	Nancy Lee, MD
10:50 am - 11:05 am	The Role of Robotic Surgery for the Management and De-escalation of HPV Positive OPC	Seungwon Kim, MD
11:05 am - 11:20 am	CTDNA in HPV Positive Oropharyngeal SCC	Jose Zevallos, MD
11:20 am - 11:30 am	Panel Discussion	
11:30 am - 12:30 pm	Lunch	
	<i>Oral Cavity SCC</i> <i>Moderator: Kevin Contrera</i>	
12:30 pm - 12:45 pm	Management of the N0 Neck	Kevin Contrera, MD
12:45 pm - 1:00 pm	Neoadjuvant Therapy	Dan Zandberg, MD
1:00 pm - 1:15 pm	Adjuvant Therapy for Oral Cancer	Christopher Wilke, MD
1:15 pm - 1:45	Panel: Oral Cavity Cases	

***Rare Tumors in the Head and Neck: Salivary Gland,
Nasopharyngeal, and Paranasal Sinuses***
Moderator: Garret Choby

1:45 pm – 2:00 pm	Advances in Molecular Diagnostics for Salivary Gland Cancers	Diana Bell, MD
2:00 pm- 2:15 pm	Surgery for Paranasal Sinus Tumors	Garrett Choby, MD
2:15 pm- 2:30 pm	Systemic Therapy as Part of Multimodality Definitive Therapy in Nasopharyngeal Carcinoma	Dan Zandberg, MD
2:30 pm -2:40 pm	Panel discussion	
2:40 pm – 2:50 pm	Break	

Management of the Locoregional Recurrence
Moderator: Mathew Spector

2:50 pm – 3:05 pm	Proper Selection of Patients with Recurrent Cancers Who May (or May Not) Benefit from Surgical Resection	Matthew Spector, MD
3:05 pm- 3:20 pm	Role of Reirradiation in the Treatment of Recurrent or Metastatic Head and Neck Cancer	Yvonne Mowery MD
3:20 pm- 3:35 pm	Systemic Therapy for R/M HNSCC	Dan Zandberg, MD
3:35 pm – 3:50 pm	Panel – Recurrent and Metastatic Cases	

Other Important Topics in Head and Neck Cancer
Moderator: Dan Zandberg

3:50 pm – 4:05 pm	Importance of Survivorship Care in the Post-Treatment Management of Head and Neck Cancer Patients	Marci Nilsen, RN
4:05 pm – 4:20 pm	Updates on Reconstruction	Mathew Spector, MD
4:20 pm	Adjournment	